Lineage Cell Therapeutics
LCTX
LCTX
102 hedge funds and large institutions have $142M invested in Lineage Cell Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.6% more ownership
Funds ownership: 36.72% → 37.32% (+0.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
32% less call options, than puts
Call options by funds: $400K | Put options by funds: $588K
Holders
102
Holding in Top 10
3
Calls
$400K
Puts
$588K
Top Buyers
| 1 | +$2.64M | |
| 2 | +$2.52M | |
| 3 | +$2.03M | |
| 4 |
BlackRock
New York
|
+$2.03M |
| 5 |
Two Sigma Investments
New York
|
+$1.66M |
Top Sellers
| 1 | -$1.52M | |
| 2 | -$1.11M | |
| 3 | -$278K | |
| 4 |
Capstone Investment Advisors
New York
|
-$251K |
| 5 |
LWM
Laidlaw Wealth Management
New York City,
New York
|
-$129K |